DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Getting to Market Quicker: U.S. Physician and Payer Perceptions of Breakthrough Designation for Malignant Melanoma, Breast Cancer, NSCLC, Chronic Lymphocytic Leukemia, and Multiple Myeloma | Physician & Payer Forum | US | 2014
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Global Consequences of Smoking Cessation: NSCLC Incidence over the Next Two Decades
The strongest risk factor that drives change in the incidence of non-small-cell lung cancer (NSCLC) is the historical prevalence of smoking. The long lag between the initiation of tobacco use and…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | Decision Base | US/EU | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | DecisionBase | US/EU5/Asia Pacific | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Contemporary Topics in the Treatment of Non-Small-Cell Lung Cancer: Physicians, Payers, and Pathologists as Gatekeepers to Market Access
Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…
